This week in psychedelic policy: a silent FDA panel, the American Legion's S.4220 claims, and Alabama's four-month rescheduling hold.

New JAMA data on the Oregon psilocybin program lands as fee hikes threaten it. Plus Heidi Overton's FDA nomination and J&J's $85M Delix round.

Resilient Pharmaceuticals resubmits its MDMA NDA to the FDA. Canada funds a C$24M brain health consortium. Definium's oral LSD clears Phase 3.

YouTube video by Marissa

This week in psychedelic policy: the VA's five-site psilocybin trial, a Senate vote delaying the hemp THC ban, and FDA's final trial guidance

An Ohio State pilot trial of psilocybin for veterans with PTSD reported remission in nine of twelve participants at one month.

Watch JOURNEYS your way—on Vimeo or in community—then join Psychedelics Today for a live Q&A discussion with the creative team.

Psychedelic policy this week: the House extends military research to 2033, blocks Right to Try, and the FDA may revisit MDMA.

Psychedelic policy this week: Texas ibogaine trials, Eli Lilly's $3.8B AtaiBeckley deal, a Miami retreat death charge, and Diné opposition to mescaline plans.

The biologist’s bold “energetic view of life” looks to the body’s strangest organelles as the link between cells, health, and mind and the foundation of our experience of being alive.

Gabon's new iboga decree puts sovereignty and reciprocity at the center of the ibogaine boom. A view from inside the Gabonese government.

The IBOGAINE Act, Oregon psilocybin fee hikes, DEA action on 7-OH, and MKUltra testimony in this week's psychedelic policy briefing.

The 8-Circuit Model of Consciousness offers psychedelic practitioners a map for the states clinical frameworks can't hold.

Italy's forgotten psychedelic history is resurfacing. Inside its research, policy, and the fight to keep these therapies public.

North Carolina, New Hampshire, and Illinois advance psychedelic policy bills on psilocybin, MDMA, and ibogaine research for veterans and trauma care.

Federal psychedelic policy in 2026 divides over veterans access. Congress pushes MDMA and psilocybin research while the DEA bans analogs and stalls rescheduling. Inside the contradiction shaping psych...

Safar founder Sabba Nazhand. Why AI in mental health care should work beside therapists, not replace them, and the risks builders must face.

State-by-state breakdown of 2026 psychedelic policy: ibogaine research, pilot programs, benefit sharing, and the political fights shaping legal access.

Utah's HB 390 funds clinical research into MDMA, psilocybin, and 5-MeO-DMT for veterans with treatment-resistant PTSD. What the law does and does not do.

Federal leaders, veterans advocates, and investors gathered in D.C. to work through what it will actually take to implement psychedelic medicine at scale.

Join us at the Shulgin Farm for an intimate conversation to learn directly from those who shaped the movement’s foundations.

Learn how music shapes psychedelic-assisted therapy, from playlist design and emotional arc to ketamine, psilocybin, and emerging research.

People who frequently pray or read religious texts in private tend to experience lower blood pressure spikes when stressed. A new study provides evidence that specific religious behaviors, rather than general spirituality, help regulate the body's stress response.

Europes biggest event for mental health, psychedelic science, wellness, festival and human flourishing. ADVANCE YOUR MIND – EXPAND YOUR WORLD May 15–17, 2026 · Funkhaus Berlin

Andrew Feldmár argues that psychedelic psychotherapy begins with relationship, not protocol, certainty, or promises of cure.

Erica Rex discusses Seeing What Is There, trauma, integration, psychedelic hype, and the limits of psychiatric medicine.

Trump’s April 2026 executive order speeds psychedelic drug review and research, but stops short of legalization, approval, or insurance coverage.

This paper should be a bigger deal than it probably will be.

MAPS co-executive directors Betty Aldworth and Ismail Ali discuss leadership, research, policy, and the future of MAPS.

Utah Gov. Spencer Cox signed H.B. 390 into law, authorizing a tightly regulated psychedelic therapy study for veterans with treatment-resistant PTSD at Huntsman.

Expanding Horizons in Mental Health: Psychedelics, Depth, and the Human Psyche

Jen Davenport joins Psychedelics Today to interview the CEO and co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to e...